---
title: "Veradigm | 8-K: FY2024 Revenue: USD 594.4 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287674829.md"
datetime: "2026-05-26T20:14:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287674829.md)
  - [en](https://longbridge.com/en/news/287674829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287674829.md)
---

# Veradigm | 8-K: FY2024 Revenue: USD 594.4 M

Revenue: As of FY2024, the actual value is USD 594.4 M.

EPS: As of FY2024, the actual value is USD -2.7.

#### Historical Financial Performance (2024 vs. 2023)

#### Total Revenue

Allscripts 医疗 (Veradigm Inc.) reported total revenue of $594.4 million in 2024, a decrease from $626.0 million in 2023, with the 2023 revenue including $19.0 million of non-recurring revenue from settlements.

#### Segment Revenue

-   Provider Segment Revenue was $473.1 million in 2024, down from $492.1 million in 2023.
-   Payer Segment Revenue was $67.3 million in 2024, decreasing from $72.3 million in 2023.
-   Life Science Segment Revenue stood at $54.0 million in 2024, a decline from $61.6 million in 2023.

#### Net Income (Loss)

Allscripts 医疗 (Veradigm Inc.) reported a Net Loss of - $291.6 million in 2024, compared to Net Income of $49.2 million in 2023, primarily due to an impairment of goodwill and other assets, as well as transaction and other costs.

#### Adjusted EBITDA

Adjusted EBITDA was $94.1 million in 2024, a decrease from $131.5 million in 2023.Adjusted EBITDA Margin was 15.8% in 2024, down from 21.7% in 2023.

#### Gross Profit and Margin (GAAP)

Gross Profit was $302.2 million in 2024, a decline from $341.5 million in 2023.Gross Margin was 50.8% in 2024, down from 54.6% in 2023.

#### Operating Expenses

-   Selling, general and administrative expenses were $269.4 million in 2024, an increase from $200.9 million in 2023.
-   Research and development expenses totaled $108.3 million in 2024, up from $97.0 million in 2023.
-   Impairment of goodwill and other assets was $108.2 million in 2024, significantly higher than $0.2 million in 2023.
-   Amortization of intangibles was $11.0 million in 2024, an increase from $8.7 million in 2023.

#### Income (Loss) from Operations

Allscripts 医疗 (Veradigm Inc.) reported Income (loss) from operations of - $194.7 million in 2024, compared to $34.7 million in 2023.

#### Balance Sheet Highlights (as of December 31)

-   Cash and cash equivalents were $294.3 million in 2024, down from $446.6 million in 2023.
-   Total Assets decreased to $1,352.3 million in 2024 from $1,572.9 million in 2023.
-   Total Liabilities increased to $548.3 million in 2024 from $498.4 million in 2023.
-   Total Stockholders’ Equity was $804.0 million in 2024, a decrease from $1,074.5 million in 2023.
-   Long-term debt was $72.2 million in 2024, compared to $0.0 million in 2023.

#### Cash Flow

Operating cash flow and free cash flow data were not provided in the reference for historical performance.

#### Outlook / Guidance

Allscripts 医疗 (Veradigm Inc.) anticipates its 2026 full-year revenue will improve due to a more focused product and platform strategy, with profitability positively influenced by AI-specific investments and cost actions initiated in fall 2025. For 2025, the company estimates total revenue to be in the range of $584 million to $589 million. Additionally, Net Cash is projected to be $45 million by year-end December 31, 2025, consisting of $120 million in cash and cash equivalents and $75 million in debt.

### Related Stocks

- [MDRX.US](https://longbridge.com/en/quote/MDRX.US.md)

## Related News & Research

- [Healthcare and 2 other lagging sectors to buy](https://longbridge.com/en/news/288374241.md)
- [Trump issues final rule requiring most Medicaid beneficiaries to work](https://longbridge.com/en/news/288333469.md)
- [Norges Bank Invests $549.16 Million in Agilent Technologies, Inc. $A](https://longbridge.com/en/news/288248789.md)
- [Is Cognizant (CTSH) Quietly Recasting Its Moat Around Agent‑Ready AI Infrastructure in Healthcare and Travel?](https://longbridge.com/en/news/288309886.md)
- [11:32 ETFirstsource and AppliedAI Report Real-World Results from Strategic Partnership](https://longbridge.com/en/news/288299382.md)